Raymond James & Associates Ovid Therapeutics Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding OVID
# of Institutions
75Shares Held
39MCall Options Held
37.4KPut Options Held
500-
Rubric Capital Management LP New York, NY5.32MShares$5.53 Million0.17% of portfolio
-
Madison Avenue Partners, LP New York, NY4.12MShares$4.28 Million0.6% of portfolio
-
Black Rock Inc. New York, NY3.99MShares$4.15 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.85MShares$4.01 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.14MShares$3.27 Million0.0% of portfolio
About Ovid Therapeutics Inc.
- Ticker OVID
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,419,400
- Market Cap $73.2M
- Description
- Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...